IMAGE ANALYSIS GROUP’s Post

How has the situation improved for healthcare IPOs and funding? https://lnkd.in/ecGdV_ky 💬 “Biotech and MedTech can find more funding, bigger funding, and for longer periods.” Vincent Meunier, Healthcare Managing Director at Bryan Garnier.  Watch our most recent feature on BSMART, where Vincent discusses:  🧬 Upcoming biotech IPOs  📈 A renewed interest in M&A Activity  💊 The ambitious moves and goals of AstraZeneca 🎥 Watch the full video with English subtitles here: https://lnkd.in/ecGdV_ky #IPOs #ECM #Healthcare #AstraZeneca #IndustryInsights #BSMART #SmartBourse #BryanGarnier

We will be in San Francisco in January for the 2024 Biotech Showcase conference. During the event, hear from Parexel’s President and Global Head - Biotech, Jim Anthony, and Senior Vice President and Worldwide Head - Access Consulting, Wyatt Gotbetter. For more information or to schedule a meeting, use this link. Comment below if I’ll see you there! #biotechshowcase #biotechshowcase2024 #biotech #healthcare

Reflecting on JPM 2024 - a barometer of the future of healthcare and how DeSci is quietly making its mark in the healthcare industry. Alongside pharma giants like Novartis, Eli Lilly and Company, Pfizer, and the like, Molecule joined the conversation on healthcare, particularly with regard to Decentralized Science and its integration into mainstream pharma. DeSci’s momentum at JPM2024 was unmistakable. Apart from AthenaDAO's presence, a DeSci meetup hosted by Molecule, Atria Ventures, Pfizer Ventures, and Fifty Years attracted around 200 external minds, united in their curiosity for this emerging field. Paul Kohlhaas led the discussion on DeSci and Molecule’s work in this field (such as the IP-NFT and IPT infrastructure & @bio_xyz). The goal? To develop and normalize innovative frameworks for scientific collaboration and funding. We are grateful for the chance to have shared our vision for scientific research and funding, and want to give a special thanks to Fifty Years, Pfizer Ventures and Atria Ventures for hosting the DeSci meetup with us, and for everyone who attended. If you want to follow up with a conversation, join our Discord, DM us, or send an email to [email protected] Here’s to a future where DeSci revolutionizes healthcare. 🥂 https://lnkd.in/eTP2TtAb

Embarking on DCTs and ACTs will force pharma companies to adopt new digital technologies to collect new types of data, and embrace new approaches, technologies and skills. Join our keynote session where we share how to design and realise DCTs. How to plan your product strategy and keep patients, investigators, and HCPs at the center as you design. https://lnkd.in/d_V6YZBk #GetTheFutureYouWant #BiotechXEurope2023 #BiotechXinBasel Thorsten Alexander Rall

I’ll be in San Francisco in January for the 2024 Biotech Showcase conference. During the event, hear from Parexel’s President and Global Head - Biotech, Jim Anthony, and Senior Vice President and Worldwide Head - Access Consulting, Wyatt Gotbetter. For more information or to schedule a meeting, use this link. Comment below if I’ll see you there! #biotechshowcase #biotechshowcase2024 #biotech #healthcare

I’ll be in San Francisco in January for the 2024 Biotech Showcase conference. During the event, hear from Parexel’s President and Global Head - Biotech, Jim Anthony, and Senior Vice President and Worldwide Head - Access Consulting, Wyatt Gotbetter. For more information or to schedule a meeting, use this link. Comment below if I’ll see you there! #biotechshowcase #biotechshowcase2024 #biotech #healthcare

I’ll be in San Francisco in January for the 2024 Biotech Showcase conference. During the event, hear from Parexel’s President and Global Head - Biotech, Jim Anthony, and Senior Vice President and Worldwide Head - Access Consulting, Wyatt Gotbetter. For more information or to schedule a meeting, use this link. Comment below if I’ll see you there! #biotechshowcase #biotechshowcase2024 #biotech #healthcare

I’ll be in San Francisco in January for the 2024 Biotech Showcase conference. During the event, hear from Parexel’s President and Global Head - Biotech, Jim Anthony, and Senior Vice President and Worldwide Head - Access Consulting, Wyatt Gotbetter. For more information or to schedule a meeting, use this link. Comment below if I’ll see you there! #biotechshowcase #biotechshowcase2024 #biotech #healthcare

Taking the pulse of the Biotech community is always invigorating. BIO meetings serve as ideal platforms to assess the landscape through various channels: one-on-one partnering meetings, networking in the exhibition hall, and attending conferences. In Barcelona last week, there was a palpable sense of optimism compared to previous years. Now, there's a widespread recognition that the bar for success in the biotech community has been raised. Attention and funding are now reserved for endeavors showcasing exceptional science and robust development. Down the value chain, stakeholders increasingly agree that true value emerges when innovation becomes accessible to patients. While this may seem obvious, for years, there was an implicit assumption that the journey ended with the completion of clinical programs or an IPO. Many clinical-stage biotechs delegated this aspect to established pharmas with excuses like "Not my business" or "too complicated." Consequently, they failed to realize the full value of their assets, resulting in lower financial returns, limited medical insights, and minimal patient feedback. Giving access to patients supposes to have a strategy up to patient, i.e. a go-to-market strategy. It supposes also to have the right capabilities availables to execute the plan. The later is most challenging part. It's time for a fresh perspective! Xcube.bio focuses on European market-entry for late-stage biopharma. Its value proposition brings down the risk and cost of European set up through a unique blend of financial engineering, equity and deep-tech enablers. Ultimately, we deliver a functioning European entity with sustainable revenue stream to Biopharma partners. Visit us https://xcube.bio #biopharma, #emergingbiopharma, #launch, #incubator

Excited for the 7th Alcor Drug Discovery Platform Summit under the esteemed leadership of our Chairman for Day 1, Abdulkader Rahmo, who serves as President & CSO SMSbiotech. As we convene for this premier event, we embark on a collective journey of exploration, collaboration, and innovation in the dynamic realm of drug discovery. Under Chairman Rahmo's visionary guidance, this summit promises to be a nexus of cutting-edge research, insightful discussions, and invaluable networking opportunities. Join us as we unite with leading experts, industry pioneers, and visionaries to chart the course for the future of drug discovery. This summit isn't just about presentations—it's a convergence of minds dedicated to driving progress, shaping the future, and making a meaningful impact on global health. Let's elevate the discourse, ignite innovation, and propel the field of drug discovery to new heights. Together, we're shaping a healthier, brighter tomorrow. #AlcorDrugDiscovery #Summit #Innovation #ADDP2024 #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits